Pearls and pitfalls of intraarterial chemotherapy for retinoblastoma.
Retinoblastoma is a deadly eye cancer in children, leading to death in 50%-70% of children in undeveloped nations who are diagnosed with it. This malignancy is the most common intraocular tumor in childhood worldwide. The good prognosis in developed nations is related to early detection and advanced treatments. With the advent of intraarterial chemotherapy, neurosurgeons have taken a central role in the treatment of this pediatric condition. Intraarterial chemotherapy is a novel treatment for retinoblastoma whereby chemotherapeutic agents are precisely delivered into the ophthalmic artery, minimizing systemic toxicity. This procedure has shown impressive results and has allowed a dramatic decrease in the rate of enucleation (eye removal) in advanced and refractory retinoblastoma. Recent reports have raised some concerns about the risk of ocular vasculopathy, radiation-related toxicity, and the potential for metastatic disease after intraarterial chemotherapy. In the authors' experience of more than 3 years, tumor control is excellent with globe salvage at 67% and vascular events less than 5%, mostly related to improvement in technique. The role of this novel approach in the management of retinoblastoma has yet to be defined. As more centers are adopting the technique, the topic will decidedly become the focus of intensive future research. In this paper, the authors review and discuss current data regarding intraarterial chemotherapy for retinoblastoma.
Department of Neurosurgery, Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, PA, USA.
Pascal
P
Jabbour
Nohra
N
Chalouhi
Stavropoula
S
Tjoumakaris
L Fernando
LF
Gonzalez
Aaron S
AS
Dumont
Rohan
R
Chitale
Robert
R
Rosenwasser
Carlos G
CG
Bianciotto
Carol
C
Shields
D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage* / Q000009:adverse effects; D015353:Eye Enucleation; D006801:Humans; D007269:Injections, Intra-Arterial / Q000379:methods*; D008558:Melphalan / Q000008:administration & dosage* / Q000009:adverse effects; D009366:Neoplasm Seeding; D009880:Ophthalmic Artery; D012107:Research Design; D019572:Retinal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012175:Retinoblastoma / Q000188:drug therapy* / Q000473:pathology
D018906:Antineoplastic Agents, Alkylating; D008558:Melphalan